TVTX
TVTX clinical trials: Travere Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Travere Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 19
- Trials linked
- 14
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TVTX on the catalyst calendar · TVTX registry changes
- Primary completion Aug 2030Sponsor estimatePhase 3NCT06431893A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of...Travere Therapeutics, Inc. · HomocystinuriaEnrolling by invitationTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT06247085Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentTravere Therapeutics, Inc. · HomocystinuriaRecruitingTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 7, 2023ActualPhase 3NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyTravere Therapeutics, Inc. · Immunoglobulin A NephropathyCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2026ActualNo phase registeredNCT02998710Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)Travere Therapeutics, Inc. · Homocystinuria Due to CBS DeficiencyCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1/Phase 2NCT03406611Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)Travere Therapeutics, Inc. · HomocystinuriaRecruitingTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 4NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc. · ProteinuriaActive, not recruitingTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2027Sponsor estimatePhase 2NCT05003986Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTravere Therapeutics, Inc. · Focal Segmental GlomerulosclerosisRecruitingTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2023ActualPhase 3NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Travere Therapeutics, Inc. · Focal Segmental GlomerulosclerosisCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 14, 2024ActualPhase 2NCT05856760A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANTravere Therapeutics, Inc. · Immunoglobulin A NephropathyCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2NCT01613118Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc. · Focal Segmental GlomerulosclerosisCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2021ActualNo phase registeredNCT02638220Cerebrotendinous Xanthomatosis (CTX) Prevalence StudyTravere Therapeutics, Inc. · Cerebrotendinous Xanthomatosis (CTX)CompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2023ActualNo phase registeredNCT05200871Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)Travere Therapeutics, Inc. · Focal Segmental GlomerulosclerosisCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2020ActualPhase 1NCT05562362Study to Evaluate the Pharmacokinetics of Oral Sparsentan SuspensionTravere Therapeutics, Inc. · Healthy SubjectsCompletedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2019ActualPhase 3NCT03041116Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN ParticipantsTravere Therapeutics, Inc. · Pantothenate Kinase-Associated NeurodegenerationTerminatedTVTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2024ActualPhase 2NCT05630612ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)University of Edinburgh · ANCA Associated VasculitisActive, not recruitingTVTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1NCT07224776Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaBrigham and Women's Hospital · Proteinuric Renal DiseaseRecruitingTVTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2029Sponsor estimateNo phase registeredNCT05368038ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramAlbert Einstein College of Medicine · Acid Sphingomyelinase DeficiencyEnrolling by invitationTVTXCollaboratorAZNCollaboratorBMRNCollaboratorSNYCollaborator+4
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT04663204A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyUniversity of Leicester · Immunoglobulin A NephropathyRecruitingTVTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2025ActualNo phase registeredNCT06548022Rare Group Problem Management PlusChildren's National Research Institute · AnxietyCompletedTVTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner